Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas
dc.contributor.author | McCoy, J. Philip Jr. | en_US |
dc.contributor.author | Papadopoulos, Stephen M. | en_US |
dc.contributor.author | Varani, James | en_US |
dc.contributor.author | McKeever, Paul E. | en_US |
dc.contributor.author | Wang, M. | en_US |
dc.date.accessioned | 2006-09-11T15:59:40Z | |
dc.date.available | 2006-09-11T15:59:40Z | |
dc.date.issued | 1995-10 | en_US |
dc.identifier.citation | McKeever, Paul E.; Varani, James; Papadopoulos, Stephen M.; Wang, M.; McCoy, J. Philip; (1995). "Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas." Journal of Neuro-Oncology 24(3): 267-279. <http://hdl.handle.net/2027.42/45382> | en_US |
dc.identifier.issn | 0167-594X | en_US |
dc.identifier.issn | 1573-7373 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45382 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7595757&dopt=citation | en_US |
dc.description.abstract | Four human astrocytic gliomas of high grade of malignancy were each evaluated in tissue and in vitro for percentages of cells expressing glial fibrillary acidic protein (GFAP), collagen type IV, laminin and fibronectin assessed by immunofluorescence with counterstaining of nuclear DNA. Percentages of cells with reticulin and cells binding fluorescein-labeled Ulex europaeus agglutinin were also assessed. In tissue, each extracellular matrix (ECM) component was associated with cells in the walls of abnormal proliferations of glioma vessels, and all four tumors had the same staining pattern. Two strikingly different patterns of conversion of gene product expression emerged during in vitro cultivation. (1). In the most common pattern, percentages of all six markers consistently shifted toward the exact phenotype of mesenchymal cells in abnormal vascular proliferations: increased reticulin, collagen type IV, laminin and fibronectin; markedly decreased glial marker GFAP and absent endothelial marker Ulex europaeus agglutinin. The simplest explanation of this constellation of changes coordinated toward expression of vascular ECM markers is that primary glioma cell cultures are overgrown by mesenchymal cells from the abnormal vascular proliferations of the original glioma. These cell cultures were tested for in situ hybridization (ISH) signals of chromosomes 7 and 10. Cells from one glioma had diploid signals. Cells from the other glioma had aneuploid signals indicating they were neoplastic; however, their signals reflected different numerical chromosomal aberrations than those common to neoplastic glia. (2). The second pattern was different. Cells with ISH chromosomal signals of neoplastic glia retained GFAP, and gained collagen type IV. Their laminin and fibronectin diminished, but persisted among a lower percentage of cells. Cloning and double immunofluorescence confirmed the presence of individual cells with glial and mesenchymal markers. A cell expressing GFAP in addition to either fibronectin, reticulin or collagen type IV is not a known constituent of glioblastoma tissue. This provides evidence of a second mechanism of conversion of gene expression in gliomas. | en_US |
dc.format.extent | 2854864 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Glioblastoma | en_US |
dc.subject.other | Extracellular Matrix | en_US |
dc.subject.other | Cell Lineage | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Collagen | en_US |
dc.subject.other | Gene Expression | en_US |
dc.subject.other | Glioma | en_US |
dc.title | Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Ophthalmology | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | The Department of Pathology, The University of Michigan Medical School, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | The Department of Pathology, The University of Michigan Medical School, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | The Department of Surgery, The University of Michigan Medical School, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | The Department of Pathology, The University of Michigan Medical School, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | The Department of Pediatrics, The University of Medicine and Dentistry of New Jersey, 08103, Camden, NJ, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 7595757 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45382/1/11060_2005_Article_BF01052843.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF01052843 | en_US |
dc.identifier.source | Journal of Neuro-Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.